New antibody targets advanced cancers in phase 2 trial
NCT ID NCT04452955
Summary
This study is testing an experimental antibody called PRL3-Zumab in people with advanced solid tumors that cannot be surgically removed or have spread. The goal is to see if the treatment is safe and can help control the cancer by measuring how long patients live without their disease getting worse. Participants receive the antibody through an IV every two weeks until the cancer progresses or side effects become too difficult.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada, 89014, United States
-
HonorHealth Research
Scottsdale, Arizona, 85258, United States
-
Norton Healthcare
Louisville, Kentucky, 40200, United States
-
St. Jude Medical Center
Fullerton, California, 92835, United States
-
The Angeles Clinic
Los Angeles, California, 90025, United States
Conditions
Explore the condition pages connected to this study.